The Management of Recurrence of Hepatocellular Carcinoma Occurring Within 6 Months After Hepatic Resection: A Comparative Study Using a Propensity Score Matching Analysis

Inoué, Yoshihiro; Suzuki, Yusuke; Ota, Masato; Kitada, Kazuya; Kuramoto, Toru; Fujii, Kensuke; Matsuo, Kentaro; Miyaoka, Yuta; Miyamoto, Terumasa; Yokohama, Keisuke; Ohama, Hideko; Imai, Yoshiro; Tanaka, Ryo; Tsuchimoto, Yusuke; Terazawa, Tetsuji; Masubuchi, Shinsuke; Yamamoto, Masashi; Asai, Akira; Shirai, Yasutsugu; Inoue, Masayasu; Fukunishi, Shinya; Nakahata, Yoshikatsu; Takii, Michiaki; Goto, Masahiro; Kimura, Fumiharu; Higuchi, Kazuhide; Uchiyama, Kazuhisa

doi:10.1007/s12029-021-00585-2

Cited by 7 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Third, a selection bias towards offering repeat resection only to those patients with a lower expected surgical difficulty. According to the literature, the incidence of intrahepatic recurrence after LR is about 50% at 5 years for patients with solitary HCC [29][30][31] and, in half of the cases, it is an early recurrence [30]. The number of recurring patients on the IGoMILS registry may be higher.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Is minimally invasive liver surgery a reasonable option in recurrent HCC? A snapshot from the I Go MILS registry

et al. 2021

View full text Add to dashboard Cite

Laparoscopic liver resection (LLR) for Hepatocellular carcinoma (HCC) is a safe procedure. Repeat surgery is more often required, and the role of minimally invasive liver surgery (MILS) is not yet clearly defined. The present study analyzes data compiled by the Italian Group of Minimally Invasive Liver Surgery (IGoMILS) on LLR. To compare repeated LLR with the first LLR for HCC is the primary endpoint. The secondary endpoint was to evaluate the outcome of repeat LLR in the case of primary open versus primary MILS surgery. The data cohort is divided into two groups. Group 1: first liver resection and Group 2: Repeat LLR. To compare the two groups a 3:1 Propensity Score Matching is performed to analyze open versus MILS primary resection. Fifty-two centers were involved in the present study, and 1054 patients were enrolled. 80 patients underwent to a repeat LLR. The type of resection was different, with more major resections in the group 1 before matching the two groups. After propensity score matching 3:1, each group consisted of 222 and 74 patients. No difference between the two groups was observed. In the subgroup analysis, in 44 patients the first resection was performed by an open approach. The other 36 patients were resected with a MILS approach. We found no difference between these two subgroups of patients. The present study in repeat MILS for HCC using the IGoMILS Registry has observed the feasibility and safety of the MILS procedure.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The number of recurring patients on the IGoMILS registry may be higher. Moreover, patients who underwent repeat hepatectomy for recurrences had a better prognosis than those who underwent other treatments [31]. Also, the IGoMILS Registry does not include open approach cases, which precludes the direct comparison of open versus LLR surgery.…”

Section: Discussionmentioning

confidence: 99%

Is minimally invasive liver surgery a reasonable option in recurrent HCC? A snapshot from the I Go MILS registry

et al. 2021

View full text Add to dashboard Cite

show abstract

“…While some studies define recurrence within 2 years after surgery as ER, others have used shorter TTRs, such as 1 year or even 6 months. [16][17][18][19] In this report, we define ER as a recurrence that occurs within 1 year. 16 In our study, we identified six differential taxa, including Dialister, Veillonella, Eubacterium coprostanoligenes group, Lactobacillus, Streptococcus pneumoniae, and Bifidobacterium faecale, whose abundance was elevated in the ER group by comparing the preoperative stool microbiome of postoperative patients with and without ER of HCC.…”

Section: Discussionmentioning

confidence: 99%

Gut microbiome as a biomarker for predicting early recurrence of HBV‐related hepatocellular carcinoma

Zheng,

Lu,

Chen

et al. 2023

Cancer Science

View full text Add to dashboard Cite

To investigate the potential of the gut microbiome as a biomarker for predicting the early recurrence of HBV‐related hepatocellular carcinoma (HCC), we enrolled 124 patients diagnosed with HBV‐associated HCC and 82 HBV‐related hepatitis, and 86 healthy volunteers in our study, collecting 292 stool samples for 16S rRNA sequencing and 35 tumor tissue samples for targeted metabolomics. We performed an integrated bioinformatics analysis of gut microbiome and tissue metabolome data to explore the gut microbial–liver metabolite axis associated with the early recurrence of HCC. We constructed a predictive model based on the gut microbiota and validated its efficacy in the temporal validation cohort. Dialister, Veillonella, the Eubacterium coprostanoligenes group, and Lactobacillus genera, as well as the Streptococcus pneumoniae and Bifidobacterium faecale species, were associated with an early recurrence of HCC. We also found that 23 metabolites, including acetic acid, glutamate, and arachidonic acid, were associated with the early recurrence of HCC. A comprehensive analysis of the gut microbiome and tissue metabolome revealed that the entry of gut microbe‐derived acetic acid into the liver to supply energy for tumor growth and proliferation may be a potential mechanism for the recurrence of HCC mediated by gut microbe. We constructed a nomogram to predict early recurrence by combining differential microbial species and clinical indicators, achieving an AUC of 78.0%. Our study suggested that gut microbes may serve as effective biomarkers for predicting early recurrence of HCC, and the gut microbial–tumor metabolite axis may explain the potential mechanism by which gut microbes promote the early recurrence of HCC.

show abstract

“…A cross-discussion or consultation with a third reader was carried out when there were disagreements. The eligibility criteria for study screening were as follows: (1) HCC patients; (2) patients who underwent MRI for MRI-based rim enhancement evaluation; (3) studies that reported prognoses such as local tumor progression (LTP)-free survival, progressionfree survival, recurrence-free survival, disease-free survival (DFS), and OS; (4) study reported correlation analysis between MRI-based rim enhancement and prognosis; (5) study was not case report, systematic review, meta-analysis, or animal study; (6) study language was English or Chinese.…”

Section: Eligibility Criteriamentioning

confidence: 99%

“…Currently, surgical resection and radiofrequency ablation (RFA) are viewed as radical treatments for early-stage HCC patients [3][4][5]. Nevertheless, the outcome of HCC patients is still unfavorable, with a 5-year recurrence rate ranging from 60 to 70% [6][7][8]. Considering that HCC is a major public health concern, prognosis prediction is crucial to promote the management of HCC patients.…”

Section: Introductionmentioning

confidence: 99%

Magnetic resonance imaging-based rim enhancement could effectually predict poor prognosis in hepatocellular carcinoma: a meta-analysis

Lu,

Cen,

et al. 2024

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Recent studies have initially shown that MRI-based rim enhancement associates with poor prognosis in hepatocellular carcinoma (HCC) patients, but their sample sizes are small, leading to a necessary of comprehensive analyses to make a relatively solid statement. Thus, this meta-analysis aimed to summarize the correlation between MRI-based rim enhancement and prognosis in HCC patients. Until March 2023, a literature search was conducted on Web of Science, PubMed, EMBASE, Cochrane, CNKI, Wangfang, and CQVIP databases in order to identify studies that report the correlation between MRI-based rim enhancement and the prognosis of HCC patients. MRI-based rim enhancement and prognostic data were extracted and analyzed. In our study, eight studies containing 1816 HCC patients were analyzed. Generally, the presence of MRI-based rim enhancement was related to shortened disease-free survival (DFS) [hazard ratio (HR): 2.77, 95% confidence interval (CI): 2.11–3.62, P < 0.001], and worse overall survival (OS) (HR: 5.43, 95% CI: 2.14–13.79, P < 0.001). While no other prognostic data could be retrieved. Funnel plots, Begg’s test, and Egger’s test all indicated that no publication bias existed; and the risk score by Newcastle-Ottawa Scale criteria ranged from 7–9 points, suggesting a generally low risk of bias. Meanwhile, the sensitivity analysis showed that the significant findings did not change by omitting each study. Then, subgroup analyses revealed that no matter stratified by tumor size, treatment option, or sample size, rim enhancement was linked with unsatisfied DFS (all P < 0.05). Conclusively, MRI-based rim enhancement could effectually estimate poor survival in HCC patients, indicating its good prognostic value.

show abstract

The Management of Recurrence of Hepatocellular Carcinoma Occurring Within 6 Months After Hepatic Resection: A Comparative Study Using a Propensity Score Matching Analysis

Cited by 7 publications

References 17 publications

Is minimally invasive liver surgery a reasonable option in recurrent HCC? A snapshot from the I Go MILS registry

Is minimally invasive liver surgery a reasonable option in recurrent HCC? A snapshot from the I Go MILS registry

Gut microbiome as a biomarker for predicting early recurrence of HBV‐related hepatocellular carcinoma

Magnetic resonance imaging-based rim enhancement could effectually predict poor prognosis in hepatocellular carcinoma: a meta-analysis

Contact Info

Product

Resources

About